EGFR Amp has been established as an independent marker for poor overall survival (OS) in IDH-wildtype lower grade gliomas, which was close to that of GBM (Aibaidula et al., 2017; Stichel et al., 2018; Petersen et al., 2021). This evidence concerns the gene EGFR and glioma.